Tradestie Institutional Equity Comparison Engine
EVGN vs CLYM โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
CLYM Overall Edge
CLYM Captures Institutional Edge (2โ0 Pillars ยท 7โ0 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Climb Bio, Inc. Common Stock (CLYM) driven by superior Growth & Margin, Momentum & Technical. Fundamentally, EVGN trades at N/M Forward P/E with -858.2% operating margin (-60.7% YoY revenue) versus CLYM at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, EVGN sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against CLYM sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
EVGN N/M vs CLYM N/M Fwd P/E
Growth & Margin Winner
CLYM
Op Margin -858.2% vs 0.0% ยท YoY -60.7% vs +0.0%
Momentum & Technical Winner
CLYM
1Y -71.9% vs +414.7% ยท 52W Pos 9% vs 49%
Options & Structure Winner
Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
EVGN
NASDAQ
Evogene Ltd.
Agricultural Chemicals
$0.34
-13.17% 1D
Market Cap
$6.0M
1M Return
-7.58%
1Y Return
-71.89%
Forward P/E
N/M
Unified AI Score
44.1 / 100
HOLD
Tech 42.0
Fund 44.0
Flow 50.0
Mom 60.0
CLYM
NASDAQ
Climb Bio, Inc. Common Stock
Pharmaceutical Preparations
$9.78
-1.61% 1D
Market Cap
$583.9M
1M Return
+0.51%
1Y Return
+414.74%
Forward P/E
N/M
Unified AI Score
51.0 / 100
HOLD
Tech 65.0
Fund 47.0
Flow 50.0
Mom 54.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
EVGN -71.89%
CLYM +414.74%
Spread: +486.63 pp (CLYM Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
EVGN TTM Op. Margin: -858.2%
CLYM TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on EVGN vs CLYM. Trailing 12-month operating profitability (EVGN -858.2% vs CLYM 0.0%) and valuation multiples (EVGN N/M vs CLYM N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | EVGN | CLYM | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $6.0M | $583.9M | Larger Scale | CLYM |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | -60.7% | +0.0% | Higher Growth | CLYM |
| Operating Margin (TTM) Profitability | -858.2% | 0.0% | Higher Margin | CLYM |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -182.8% | -29.3% | Higher ROE | CLYM |
| 52-Week Range Position Momentum | 9% ($0โ$1) | 49% ($2โ$18) | Stronger Trend | CLYM |
| Beta / 30D Volatility Risk Regime | 1.37ฮฒ ยท 138% Vol | 1.52ฮฒ ยท 112% Vol | Lower Realized Risk | CLYM |
| Unified Institutional Score Composite Signal | 44.1 / 100 (HOLD) | 51.0 / 100 (HOLD) | Higher Composite | CLYM |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full EVGN vs CLYM Buy Guide
EVGN
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
CLYM
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither EVGN nor CLYM registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.